Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 25%
Hold 63%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson's recent financial performance reflects a positive trajectory, with the Medical segment (MMS) achieving sales of $888 million in FQ3'25, marking a year-over-year growth of 5.3%, driven by robust demand in Infusion Systems and Dispensing Solutions. The company's MedTech business has consistently grown at a rate exceeding 6% annually since the launch of the BD 2025 initiative, accompanied by improving margins. Additionally, the MDS segment reported FY24 sales of $4.43 billion, reflecting a year-over-year increase of 3.2%, further solidifying the company’s strong position in the healthcare market.

Bears say

Becton Dickinson's organic revenue growth outlook has been downgraded from an initial projection of 4.0-4.5% to a range of 3.0-3.5%, indicating a more pessimistic view of future performance. In the most recent financial quarter (FQ3'25), the company reported a 1.1% year-over-year decline in sales, highlighting persistent weaknesses in key segments such as Biosciences and Diagnostic Solutions, which were further exacerbated by external pressures in China. Additionally, challenges such as reduced government research grants and slow recovery in key testing areas are expected to impose substantial growth headwinds moving forward.

BDX has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 25% recommend Buy, 63% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Hold based on their latest research and market trends.

According to 8 analysts, BDX has a Hold consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.